Stocks to watch, Nov 12: SBI, Britannia, Nykaa, Hindalco, ONGC, IRFC, LIC

Q: How long will it take to read this news story?

The story "Stocks to watch, Nov 12: SBI, Britannia, Nykaa, Hindalco, ONGC, IRFC, LIC" has 817 words across 31 sentences, which will take approximately 4 - 7 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Stocks to watch, Nov 12: SBI, Britannia, Nykaa, Hindalco, ONGC, IRFC, LIC" was covered 2 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 273 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #23540873</li><li>URL: https://beamstart.com/news/stocks-to-watch-nov-12-17313771426829</li></ul>

Business Standard Logo Business Standard 2d ago

Stocks to watch, Nov 12: SBI, Britannia, Nykaa, Hindalco, ONGC, IRFC, LIC - Business Standard

Quick Summary:

Q2 results: FSN E-Commerce Ventures (Nykaa), Hyundai Motor India, Zydus Lifesciences, Bosch, General Insurance Corporation of India, Ashoka Buildcon, Cello World, CESC, EIH, Finolex Cables, Samvardhana Motherson International, Natco Pharma, Sula Vineyards, Sunteck Realty and others will announce their September quarter earnings today.

IRFC: Indian Railway Finance Corporation (IRFC) has raised Rs 1,415 crore through bonds maturing in 15 years at a coupon rate of 7.14 per cent, as per reports.

Pharma stocks: The Indian Pharma Market (IPM) registered a 6.1 per cent value growth in October 2024 with major therapies showing positive value growth, according to a report by market research body Pharmarack.